Lucke-Wold Brandon P, Turner Ryan C, Logsdon Aric F, Simpkins James W, Alkon Daniel L, Smith Kelly E, Chen Yi-Wen, Tan Zhenjun, Huber Jason D, Rosen Charles L
Department of Neurosurgery, West Virginia University School of Medicine, Morgantown, WV, USA The Center for Neuroscience, West Virginia University School of Medicine, Morgantown, WV, USA.
The Center for Neuroscience, West Virginia University School of Medicine, Morgantown, WV, USA Department of Basic Pharmaceutical Sciences, West Virginia University School of Pharmacy, Morgantown, WV, USA.
J Alzheimers Dis. 2015;43(3):711-24. doi: 10.3233/JAD-141422.
Ischemic stroke and Alzheimer's disease (AD), despite being distinct disease entities, share numerous pathophysiological mechanisms such as those mediated by inflammation, immune exhaustion, and neurovascular unit compromise. An important shared mechanistic link is acute and chronic changes in protein kinase C (PKC) activity. PKC isoforms have widespread functions important for memory, blood-brain barrier maintenance, and injury repair that change as the body ages. Disease states accelerate PKC functional modifications. Mutated forms of PKC can contribute to neurodegeneration and cognitive decline. In some cases the PKC isoforms are still functional but are not successfully translocated to appropriate locations within the cell. The deficits in proper PKC translocation worsen stroke outcome and amyloid-β toxicity. Cross talk between the innate immune system and PKC pathways contribute to the vascular status within the aging brain. Unfortunately, comorbidities such as diabetes, obesity, and hypertension disrupt normal communication between the two systems. The focus of this review is to highlight what is known about PKC function, how isoforms of PKC change with age, and what additional alterations are consequences of stroke and AD. The goal is to highlight future therapeutic targets that can be applied to both the treatment and prevention of neurologic disease. Although the pathology of ischemic stroke and AD are different, the similarity in PKC responses warrants further investigation, especially as PKC-dependent events may serve as an important connection linking age-related brain injury.
缺血性中风和阿尔茨海默病(AD)尽管是不同的疾病实体,但却共享许多病理生理机制,例如由炎症、免疫耗竭和神经血管单元受损介导的机制。一个重要的共同机制联系是蛋白激酶C(PKC)活性的急性和慢性变化。PKC亚型具有广泛的功能,对记忆、血脑屏障维持和损伤修复很重要,并且会随着身体衰老而发生变化。疾病状态会加速PKC的功能改变。PKC的突变形式会导致神经退行性变和认知衰退。在某些情况下,PKC亚型仍然具有功能,但无法成功转运到细胞内的适当位置。PKC正确转运的缺陷会使中风预后和淀粉样β毒性恶化。先天免疫系统与PKC途径之间的相互作用会影响衰老大脑中的血管状态。不幸的是,糖尿病、肥胖症和高血压等合并症会破坏这两个系统之间的正常通讯。本综述的重点是强调关于PKC功能的已知信息、PKC亚型如何随年龄变化,以及中风和AD会导致哪些额外的改变。目的是突出未来可应用于神经疾病治疗和预防的治疗靶点。尽管缺血性中风和AD的病理不同,但PKC反应的相似性值得进一步研究,特别是因为依赖PKC的事件可能是连接与年龄相关的脑损伤的重要纽带。